C
Cora N. Sternberg
Researcher at Cornell University
Publications - 747
Citations - 57991
Cora N. Sternberg is an academic researcher from Cornell University. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 92, co-authored 663 publications receiving 48986 citations. Previous affiliations of Cora N. Sternberg include CTO Hospital & North Shore University Hospital.
Papers
More filters
Journal ArticleDOI
A phase II study investigating the safety and efficacy of neoadjuvent atezolizumab in muscle invasive bladder cancer (ABACUS)
Daniel Castellano,Ignacio Duran,Alejo Rodriguez-Vida,Simon J. Crabb,M.S. van der Heijden,A. Font Pous,Gwenaelle Gravis,U. Anido Herranz,Andrew Protheroe,Alain Ravaud,Denis Maillet,M.J. Méndez-Vidal,Cristina Suarez,Anja Lorch,Cora N. Sternberg,Mark Linch,Shah-Jalal Sarker,J. Notta,Kelly Mousa,Thomas Powles +19 more
Journal ArticleDOI
Contemporary management of metastatic castration-resistant prostate cancer.
Guru Sonpavde,Cora N. Sternberg +1 more
TL;DR: Cabazitaxel, sipuleucel-T and denosumab were approved in 2010 by regulatory agencies in the USA for men with metastatic CRPC, and approval of abiraterone acetate is anticipated based on the results of a phase III trial.
Journal ArticleDOI
Avelumab (Ave) first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): JAVELIN Bladder 100 subgroup analysis based on duration and cycles of 1L chemotherapy.
Yohann Loriot,Thomas Powles,Miguel Angel Climent Duran,Srikala S. Sridhar,Joaquim Bellmunt,Daniel P. Petrylak,Jing Wang,Nuno Costa,Robert J Laliberte,Alessandra di Pietro,Petros Grivas,Cora N. Sternberg +11 more
TL;DR: Avelumab 1L maintenance is approved in the United States for patients with advanced UC that has not progressed with 1L platinum-containing chemotherapy based on significantly prolong...
Journal ArticleDOI
Integrating cytokines and angiogenic factors and tumour bulk with selected clinical criteria improves determination of prognosis in advanced renal cell carcinoma.
Amado J. Zurita,Robert C. Gagnon,Yuan Liu,Hai T. Tran,Robert A. Figlin,Thomas E. Hutson,A M D'Amelio,Cora N. Sternberg,Lini Pandite,John V. Heymach +9 more
TL;DR: A prognostic model incorporating osteopontin, interleukin-6, TIMP-1, tumour burden, and selected clinical criteria increased prognostic accuracy for OS determination in mRCC patients.
Journal ArticleDOI
699O Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma (UC): Association between clinical outcomes and exploratory biomarkers
Thomas Powles,Y. Loriot,Joaquim Bellmunt,Cora N. Sternberg,Srikala S. Sridhar,Daniel P. Petrylak,Rosa Tambaro,L.M. Dourthe,C. Alvarez-Fernandez,Maureen J.B. Aarts,Xinmeng Jasmine Mu,Keith A. Ching,Jie Pu,S. Roychoudhury,Craig Davis,A. di Pietro,Petros Grivas +16 more